IPSEN, OOO
- Country
- 🇷🇺Russia
- Ownership
- -
- Established
- 1929-01-01
- Employees
- 5.7K
- Market Cap
- $9.8B
- Website
- https://www.ipsen.com/
Study on the Effects of Botulinum Toxin Type A on Back Muscle in Chronic Low Back Pain
- Conditions
- First Posted Date
- 2005-10-30
- Last Posted Date
- 2019-07-26
- Lead Sponsor
- Ipsen
- Target Recruit Count
- 35
- Registration Number
- NCT00246155
- Locations
- 🇰🇷
Wooridul Spine Hospital, Seoul, Korea, Republic of
Study to Define Optimal IGF-1 Monitoring in Children Treated With NutropinAq
- Conditions
- Interventions
- First Posted Date
- 2005-10-07
- Last Posted Date
- 2019-12-09
- Lead Sponsor
- Ipsen
- Target Recruit Count
- 251
- Registration Number
- NCT00234533
- Locations
- 🇧🇪
Dienst Kindergeneeskunde, Edegem, Belgium
🇬🇧University Hospital Wales, Cardiff, Wales, United Kingdom
🇫🇷Centre Hospitalier General, Le Havre, France
A Study to Evaluate the Risk of Developing a Heart Condition Called Valvular Regurgitation in Patients With Acromegaly Treated With Either Lanreotide or Octreotide
- Conditions
- First Posted Date
- 2005-10-07
- Last Posted Date
- 2019-08-02
- Lead Sponsor
- Ipsen
- Target Recruit Count
- 225
- Registration Number
- NCT00234520
- Locations
- 🇮🇹
University "Federico II" of Naples, Naples, Italy
🇧🇪Cliniques Universitaires Saint Luc, Bruxelles, Belgium
🇧🇪CHU de Liege, Liege, Belgium
Efficacy and Safety Study of Varying Doses of Lanreotide Autogel in Patients With Acromegaly
- Conditions
- First Posted Date
- 2005-10-07
- Last Posted Date
- 2019-08-02
- Lead Sponsor
- Ipsen
- Target Recruit Count
- 108
- Registration Number
- NCT00234572
- Locations
- 🇺🇸
Pituitary Center, Los Angeles, California, United States
🇺🇸Johns Hopkins University School of Medicine, Baltimore, Maryland, United States
🇺🇸Northwestern Medical Facility, Chicago, Illinois, United States
Asian Botulinum Clinical Trial Designed for Early Stroke Spasticity
- Conditions
- Interventions
- First Posted Date
- 2005-10-07
- Last Posted Date
- 2019-07-26
- Lead Sponsor
- Ipsen
- Target Recruit Count
- 162
- Registration Number
- NCT00234546
- Locations
- 🇭🇰
Prince of Wales Hospital, Shatin, Hong Kong
🇹🇭Siriraj Hospital, Bangkok, Thailand
🇲🇾University Hospital of Malaya Medical Centre, Kuala Lumpur, Malaysia
Study of a Single Administration of 3 Doses of Dysport® for the Treatment of Benign Essential Blepharospasm
- Conditions
- First Posted Date
- 2005-10-07
- Last Posted Date
- 2019-07-29
- Lead Sponsor
- Ipsen
- Target Recruit Count
- 120
- Registration Number
- NCT00234507
- Locations
- 🇺🇸
Neurological Institute, Phoenix, Arizona, United States
🇺🇸Plastic Eye Surgery Association, Pensacola, Florida, United States
🇺🇸Columbia-Presbyterian Medical Center, New York, New York, United States
Effects on Quality of Life Following Dysport Treatment in Post-stroke Spasticity of the Arm
- Conditions
- Interventions
- First Posted Date
- 2005-09-22
- Last Posted Date
- 2019-07-29
- Lead Sponsor
- Ipsen
- Target Recruit Count
- 96
- Registration Number
- NCT00216411
- Locations
- 🇦🇺
St Josephs Hospital, Auburn, New South Wales, Australia
🇦🇺Box Hill Hospital, Box Hill, Victoria, Australia
🇦🇺Austin Health, Heidelberg, Victoria, Australia
Lanreotide Autogel in Patients With Acromegaly Previously Treated With Octreotide LAR
- Conditions
- First Posted Date
- 2005-09-22
- Last Posted Date
- 2019-08-16
- Lead Sponsor
- Ipsen
- Target Recruit Count
- 8
- Registration Number
- NCT00216398
- Locations
- 🇦🇺
Westmead Hospital, Westmead, New South Wales, Australia
Efficacy and Safety of Lanreotide Microparticles as Palliative Treatment in Peritoneal Carcinomatosis
- Conditions
- Interventions
- First Posted Date
- 2005-09-22
- Last Posted Date
- 2020-11-05
- Lead Sponsor
- Ipsen
- Target Recruit Count
- 80
- Registration Number
- NCT00216372
- Locations
- 🇧🇪
Clinique Universitaire St. LUC, Bruxelles, Belgium
🇧🇪Institut Jules Bordet, Bruxelles, Belgium
🇧🇪Clinique Notre-Dame, Hermalle-sous-Huy, Belgium
Efficacy Study of Dysport® in the Treatment of Anal Fissure.
- Conditions
- First Posted Date
- 2005-09-21
- Last Posted Date
- 2020-04-29
- Lead Sponsor
- Ipsen
- Target Recruit Count
- 168
- Registration Number
- NCT00210444
- Locations
- 🇨🇿
Faculty Nemocnice-III, Brno, Czechia
🇵🇱Consulting Room of Proctology, Gdansk, Poland
🇨🇿Thomayer's Memorial Hospital, Prague, Czechia